Observational analysis reveals edaravone's therapeutic potential in mitigating doxorubicin-induced mucosal injury, highlighting its impact on SIRT1 and ACE2 pathways.
Edaravone effectively attenuates DOX-induced mucosal injury by modulating oxidative stress, inflammatory signaling, and TLR4/ACE2 pathways, suggesting therapeutic potential in mucosal protection.
No takes yet. Share an insight, caveat, or question.
Zeytinoğlu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: